Abstract
Trastuzamab (Herceptin®) is a humanized monoclonal antibody that binds to the extracellular juxtamembrane domain of Human Epidermal Growth Factor Receptor type 2 (HER2) and prevents the activation of its intracellular tyrosine kinase.1 HER2 occurs in 20–30% of invasive breast cancers and Trastuzamab inhibits the proliferation and survival of HER2 dependent tumours thereby improving disease-free survival when used in combination with chemotherapy.1 An increasing number of women diagnosed with HER2 positive breast cancer are becoming pregnant while receiving treatment with Trastuzamab. The fetal effects such as anhydramnios2 have been reported in the literature but as yet no maternal side-effects from the drug have been published. Although in general Trastuzamab is well-tolerated by patients, there is a 5% risk of cardiotoxicity.3 We report such a case in pregnancy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
